STOCK TITAN

Corbus Pharmaceuticals Holdings (CRBP) Stock News, Apr-May 2020

CRBP NASDAQ

Corbus Pharmaceuticals Holdings, Inc. reports clinical-stage drug-development news in oncology and obesity. Updates center on CRB-701, a next-generation Nectin-4 antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical, including data presentations in head and neck squamous cell carcinoma and cervical cancer, FDA interactions and Fast Track designations.

Company news also covers CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, and CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation. Recurring items include clinical trial disclosures, medical-meeting presentations, management conference appearances, governance changes and operating or financial results.

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) announced the publication of two abstracts at the EULAR 2020 E-Congress, scheduled for June 3-6, 2020. The first abstract details pre-clinical data that connects lenabasum to the inhibition of inflammasome activation, while the second outlines baseline characteristics of patients in the RESOLVE-1 study in Europe. Lenabasum is a novel oral drug designed to address inflammation and fibrosis, exhibiting promising results in various studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
none
-
Rhea-AI Summary

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) announced that CEO Yuval Cohen will present at two upcoming virtual investor conferences. The 2020 RBC Capital Markets Global Healthcare Conference is scheduled for May 19, 2020, at 10:55 AM EST, and the Jefferies Virtual Global Healthcare Conference will take place on June 4, 2020, at 11:00 AM EST. Both presentations will include a fireside chat discussion and Q&A. Audio webcasts will be available on the Corbus website, with replays archived for 90 days. Corbus focuses on developing therapies targeting the endocannabinoid system for various diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.53%
Tags
conferences
-
Rhea-AI Summary

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported Q1 2020 financial results, revealing a net loss of approximately $29.7 million and a revenue decrease to $1.8 million. The company reaffirmed that topline results from the Phase 3 RESOLVE-1 study for lenabasum in systemic sclerosis are on track for summer 2020, followed by Phase 2b cystic fibrosis data. A public offering raised $46 million in gross proceeds. Corbus is also preparing for a potential NDA submission and commercial launch of lenabasum while implementing a COVID-19 mitigation plan to maintain clinical study integrity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.97%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags

FAQ

What is the current stock price of Corbus Pharmaceuticals Holdings (CRBP)?

Corbus Pharmaceuticals Holdings (CRBP) last closed at $2.75.

What is the market cap of Corbus Pharmaceuticals Holdings (CRBP)?

The market cap of Corbus Pharmaceuticals Holdings (CRBP) is approximately $56.6M.